ketorolac has been researched along with Scoliosis in 2 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Scoliosis: An appreciable lateral deviation in the normally straight vertical line of the spine. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A retrospective review comparing patients who had postoperative ketorolac and those who did not following posterior spinal fusion and instrumentation (PSFI) for adolescent idiopathic scoliosis (AIS)." | 7.74 | Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis. ( Agrawal, S; Elerson, E; Lovejoy, JF; McClung, A; Nelson, T; Sucato, DJ, 2008) |
| "A retrospective review comparing patients who had postoperative ketorolac and those who did not following posterior spinal fusion and instrumentation (PSFI) for adolescent idiopathic scoliosis (AIS)." | 3.74 | Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis. ( Agrawal, S; Elerson, E; Lovejoy, JF; McClung, A; Nelson, T; Sucato, DJ, 2008) |
| "Variation in postoperative pain management for children undergoing PSF for AIS likely impacts outcomes." | 1.46 | The Association Between Adjuvant Pain Medication Use and Outcomes Following Pediatric Spinal Fusion. ( Cohen, M; Erickson, M; Errico, T; McLeod, L; Rosenberg, RE; Trzcinski, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosenberg, RE | 1 |
| Trzcinski, S | 1 |
| Cohen, M | 1 |
| Erickson, M | 1 |
| Errico, T | 1 |
| McLeod, L | 1 |
| Sucato, DJ | 1 |
| Lovejoy, JF | 1 |
| Agrawal, S | 1 |
| Elerson, E | 1 |
| Nelson, T | 1 |
| McClung, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections: a Prospective Double-Blinded Randomized Trial[NCT04895280] | Phase 4 | 400 participants (Anticipated) | Interventional | 2024-04-30 | Not yet recruiting | ||
| Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial[NCT04115644] | Phase 4 | 82 participants (Actual) | Interventional | 2017-05-01 | Terminated (stopped due to Covid-19 and we failed to submit annual report for 2017 and 2018) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pain as measured by the Visual Analog Scale after first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Baseline - immediately after the injection
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.197 |
| Group 2 (Ketorolac) | 3.577 |
| Group 3 (Kenalog) | 3.677 |
Pain as measured by the Visual Analog Scale prior to first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Baseline - pre-injection
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 5.77 |
| Group 2 (Ketorolac) | 4.57 |
| Group 3 (Kenalog) | 4.67 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Day 2
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 2.347 |
| Group 2 (Ketorolac) | 2.837 |
| Group 3 (Kenalog) | 2.67 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 1
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.397 |
| Group 2 (Ketorolac) | 3.7 |
| Group 3 (Kenalog) | 3.257 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 12
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.447 |
| Group 2 (Ketorolac) | 1.417 |
| Group 3 (Kenalog) | 2.027 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 2
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.547 |
| Group 2 (Ketorolac) | 2.67 |
| Group 3 (Kenalog) | 2.57 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 4
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.547 |
| Group 2 (Ketorolac) | 2.67 |
| Group 3 (Kenalog) | 2.317 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 6
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.357 |
| Group 2 (Ketorolac) | 2.757 |
| Group 3 (Kenalog) | 2.687 |
2 other studies available for ketorolac and Scoliosis
| Article | Year |
|---|---|
The Association Between Adjuvant Pain Medication Use and Outcomes Following Pediatric Spinal Fusion.
Topics: Adolescent; Analgesics, Opioid; Child; Female; gamma-Aminobutyric Acid; Hospitals, Pediatric; Humans | 2017 |
Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Bone Transplantation; Child; Female; Humans; Il | 2008 |
Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Bone Transplantation; Child; Female; Humans; Il | 2008 |
Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Bone Transplantation; Child; Female; Humans; Il | 2008 |
Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Bone Transplantation; Child; Female; Humans; Il | 2008 |